Efficacy signals observed will not achieve ESSA's target product profile in patients with metastatic castration-resistant prostate cancer naïve to second-generation antiandrogens A futility analysis ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback